Cross-Sector entity
The clearest coverage concentration is regulation: 6 of 7 stories, with the rest divided among 1 other category. MMJ International Holdings is most often covered alongside Duane Boise, which appears in 7 of these 7 stories. The 30-day window averages about 1.6 stories each week. The busiest single day carried 4.
7 verified stories tracked
Last mentioned: Aug 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 43 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is regulation: 6 of 7 stories, with the rest divided among 1 other category. MMJ International Holdings is most often covered alongside Duane Boise, which appears in 7 of these 7 stories. The 30-day window averages about 1.6 stories each week. The busiest single day carried 4. MMJ International Holdings appears in 7 tracked Cross-Sector stories published from July 12, 2026 through August 10, 2026. The tracked stories average 1.4 original sources each. 14% of these stories carry negative sentiment.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MMJ International Holdings. Shared-story counts are live from our verified record — not editorial picks.
Post-Hearing Briefs Due
Parties submit final briefs to Administrative Law Judge Derek C. Julius, summarizing their arguments on the evidentiary record and legal standards. The recommendation on rescheduling is expected to follow shortly thereafter.
Rescheduling Hearing Testimony
Under subpoena, Dr. Akinfiresoye testifies in the marijuana rescheduling proceeding that marijuana fails the first three factors of the DEA's five-factor test, directly contradicting the HHS Schedule III recommendation.
ALJ Hearing on Marijuana Rescheduling
A seven-day administrative hearing is held in Arlington, Virginia, debating whether marijuana has a 'currently accepted medical use' without MMJ's testimony or evidence.
DEA Excludes MMJ from Rescheduling Hearing
The DEA denies MMJ International Holdings' request to participate in the upcoming administrative hearing, asserting that its evidence raises only questions of law.
DEA Scientific Data Review Published
Dr. Luli Akinfiresoye authors the DEA's internal Scientific Data Review on marijuana, reportedly concluding that marijuana lacks sufficient, reproducible scientific evidence for accepted medical use.
ALJ Julius's upcoming recommendation in the DEA marijuana rescheduling hearing may challenge the government's novel approach of limiting Schedule III status to state-licensed medical programs, after DEA scientist testimony cast doubt on whether such programs satisfy the Controlled Substances Act's rigorous medical-use standard.
Source: nashvilleherald.com · pittsburghstar.com
DEA pharmacologist Dr. Luli Akinfiresoye testified that marijuana fails the agency's historical scientific standard for accepted medical use, directly contradicting the HHS recommendation to reschedule. This intra-agency conflict exposes the proposed Schedule III rule to a likely arbitrary-and-capricious challenge, redefining the evidentiary landscape for controlled substance rulemaking.
Source: newjerseytelegraph.com · pr-inside.com
MMJ International Holdings alleges the DEA violated administrative law by excluding it from marijuana rescheduling hearings, despite spending $10 million on FDA-pathway development. The exclusion raises due process and APA concerns that could imperil the final rule.
Source: saltlakecitysun.com · memphissun.com
Investors are watching the D.C. Circuit case closely as MMJ International Holdings claims marijuana rescheduling would deliver over $2 billion in annual tax savings to multi-state operators, potentially boosting profitability and stock prices.
MMJ International Holdings' latest filing reveals that up to $2.24 billion in annual 280E tax overpayments could be reversed, plus $1.6B in accrued unpaid taxes forgiven—a sum that would transform balance sheets for cash-strapped cannabis startups.
The potential elimination of 280E taxes on cannabis businesses could inject over $2 billion annually into the biotech sector, accelerating cannabinoid drug development. MMJ International Holdings' latest press release quantifies the stakes.
MMJ International Holdings says moving cannabis to Schedule III would wipe out $2.24B in annual excess 280E taxes, unlocking capital for patient programs and medical research. The legal dispute spotlights the massive healthcare economic stakes of drug scheduling.
Source: finanznachrichten.de
